Kristie Harrington
Family · Springfield, MANPI 1962956649
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,490 of the $18,295 with a category attached, or 79.2%. AbbVie accounts for 87.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $12,829 and has fallen 92.0% since, to $1,026 in 2025. Among family clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $358.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Lundbeck LLC$412
- Teva Pharmaceuticals USA, Inc.$341
- Harmony Biosciences LLC$341
- Neurocrine Biosciences, Inc.$234
- Pfizer$177
- plus $829 from 11 others
What the payments were for
- Speaking & faculty fees$14,49079%
- Travel & lodging$7744%
- Food & beverage$2,76115%
- Education$2701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 21 | $15,961 |
| Lundbeck LLC | 4 | $412 |
| Teva Pharmaceuticals USA, Inc. | 3 | $341 |
| Harmony Biosciences LLC | 5 | $341 |
| Neurocrine Biosciences, Inc. | 2 | $234 |
| Pfizer | 2 | $177 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $128 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $124 |
| Novartis | 1 | $103 |
| Impel Pharmaceuticals Inc. | 2 | $89 |
| Lilly USA, LLC | 1 | $87 |
| MDD US Operations, LLC | 1 | $64 |
| ZOLL Respicardia, Inc. | 2 | $30 |
| Noctrix Health, Inc. | 1 | $30 |
| Argenx US, Inc. | 1 | $28 |
| Biogen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,295 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 54 | $262,370 |
| IngrezzaValbenazine Tosylate | 27 | $212,793 |
| UbrelvyUbrogepant | 119 | $174,286 |
| RytaryCarbidopa/Levodopa | 113 | $140,040 |
| Emgality PenGalcanezumab-Gnlm | 144 | $119,320 |
| Nurtec OdtRimegepant Sulfate | 46 | $87,065 |
| CopaxoneGlatiramer Acetate | 14 | $79,301 |
| Aimovig AutoinjectorErenumab-Aooe | 89 | $72,301 |
| NourianzIstradefylline | 36 | $69,667 |
| Droxidopa | 26 | $58,622 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 20 | $23,455 |
| QuliptaAtogepant | 18 | $19,313 |
| Memantine Hcl ErMemantine Hcl | 230 | $16,740 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 430 | $13,959 |
| NeuproRotigotine | 11 | $9,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $234 | $212,79327 claims |
| AbbVieUbrelvy, Qulipta | $15,961 | $193,599137 claims |
| PfizerNurtec Odt | $177 | $87,06546 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $341 | $79,30114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.
Other family in Springfield
- Ashley CraneSpringfield$14K
- Sage DowSpringfield$14K
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.